Bioventus BVS Insider Ownership

Updated Oct 10, 2026

Over the trailing 12 months, BVS insiders sold $312,352 worth of shares (39.7K shares) in open-market trades, with no open-market purchases.

• A count shows 2 insiders selling BVS stock on the open market over the past 12 months and none buying.
• Michelle McMurry-Heath (Director) led open-market sales of Bioventus stock over the past 12 months with $236,694 (29.7K shares), most recently on March 11, 2026.
• Beyond open-market trades, insiders at Bioventus acquired 249.18K shares through option exercises and conversions and gave up 79.53K shares to cover taxes or exercise prices in the last 12 months.
• Business Quant data puts insider holdings in BVS at 8.61Mn shares across insiders' latest Form 4 filings, unchanged from 8.61Mn shares at the end of Q2 2026 and up 4.59% from 8.23Mn shares at the end of Q3 2025.
• Bioventus insiders hold 1.67Mn shares directly (19.37% of their total) and 6.94Mn shares (80.63%) indirectly, through entities such as trusts and partnerships.
• Per Business Quant, 13 insiders of BVS hold shares, counting officers, directors and 10% owners who have filed a Form 4 in the past two years.
• BVS's three largest insider shareholders, per their latest Form 4 filings, are John A. Bartholdson (Director and 10% owner, 7.05Mn shares), William A. Hawkins (Director, 297.64K shares) and Mark Leonard Singleton (SVP & CFO, 177.33K shares).
• The holding of John A. Bartholdson makes up 81.93% of all shares held by Bioventus insiders.
• Institutional holders reported 78.92% of Bioventus' outstanding shares for Q2 2026; insiders' latest Form 4 filings put their stake at about 10.25%, and other investors, including the public, hold the remaining 10.83%.
• A total of 21 Form 4 filings with transactions in Bioventus stock were made over the past 12 months, by 14 insiders.
• The insider data for BVS reflects Form 4 filings through June 4, 2026.